Cure Countdown

JULY 15, 2021: AGT receives a unanimous vote to continue AGT’s HIV cure program without modification after safety analysis of the participant’s data revealed no adverse effects from AGT103-T. 

Tony Fauci and Jeff Galvin discuss the past, present, and future of HIV on the BIO podcast.


After the first three participants in the HIV cure human trial showed no serious adverse events, the DSMB allowed acceleration of the trial.

Our Vision for an HIV Cure

HIV Cure Project Initiated: October 2016. AGT meets with the FDA and defines a path forward for AGT103-T. FDA outlines safety requirements and greenlights further development.

IND Submission: October 2019. The Investigational New Drug (IND) application provides preclinical data and a rationale for why this unique immuno-regulatory approach is worthy of advancing into the clinic.

IND Approved - Clinical Trials Begin: August 2020, FDA approves the IND and clears AGT to begin a Phase 1 human trial.

First Patient Enrolled - October 2020. AGT begins the Phase 1 trial for AGT103-T, and the first trial participant is expected to be infused early in 2021.

Initial Safety Data - July 2021. The first participant experiences no adverse events; USMB reviews safety data and approves continuation of study.

Subscribe to our YouTube Channel

Watch clips from AGT's red carpet event celebrating its IND submission to the FDA.

Subscribe to our YouTube Channel

Cutting Edge Methods to Kill Cancer

AGT’s innovative immuno-oncology program aims to create genetic drugs that increase treatment potency, broaden the range of cancers treated, and provide the greatest value for patients. This led to the development of the ImmunoTox program, a genetic medicine introduced by a lentiviral vector delivered to sites of solid tumor growth where it penetrates tumor cells and alters their normal metabolism. The ImmunoTox program’s novel approach causes the build up of a small molecule danger signal that activates γδ T cells to kill cancer cells.

Who We Are

American Gene Technologies International Inc. (AGT) is a private biotechnology company pursuing cures and treatments for infectious diseases, cancers and monogenic disorders.
AGT's programs are designed to:

Create immunotherapy for HIV disease with gene modified T cells
Activate innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology
Treat PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation
Advance clinically to provide human proof of concept

What We Do

For over a decade, AGT has developed, tested and banked thousands of lentiviral vectors that can be adapted to the specific needs of new target diseases. AGT has developed gene therapy for diseases using this rapid gene delivery platform.

Gene Therapies

AGT’s platform allows it to pursue clinical “cures” for complex diseases. The company has developed patent-protected gene therapeutics that are breakthroughs in medicine.



Immunotherapy for HIV disease with gene modified T cells


Activates innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology


Phenylketonuria (PKU)

Treats PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation


American Gene Technologies™ (AGT) is building a rich product pipeline based on its lentiviral vector platform. Our three lead programs are well into the laboratory phase and scheduled to move into the clinic over the coming months.

Subscribe to our YouTube Channel

AGT's Core Objectives

Leverage our lentivirus platform to create highly-effective targeted genetic medicines
Create solutions for patients across a spectrum of infectious diseases, cancers and inherited disorders
Collaborate with leading medical researchers from around the globe
Partner with pharmaceutical and biotech firms on indication and platform-specific opportunities
Enhance our proprietary platform to expedite drug development